Skip to Content

GB Sciences Inc GBLX

Morningstar Rating
$0.01 0.00 (15.38%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

GBLX is trading at a 40% discount.
Price
$0.01
Fair Value
$2.43
Uncertainty
Extreme
1-Star Price
$2.69
5-Star Price
$2.18
Economic Moat
Kcbqg
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if GBLX is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$0.01
Day Range
$0.010.01
52-Week Range
$0.010.02
Bid/Ask
$0.01 / $0.01
Market Cap
$2.23 Mil
Volume/Avg
32,111 / 190,977

Key Statistics

Price/Earnings (Normalized)
Price/Sales
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield
6.34%

Company Profile

GB Sciences Inc is active in the healthcare sector. The company is engaged in developing and utilizing technologies in plant biology, cultivation, and extraction techniques combined with biotechnology, and plans to produce medical-grade cannabis, cannabis concentrates, and cannabinoid therapies. It seeks to be a technology and solution company that converts the cannabis plant into medicines, therapies, and treatments for a range of ailments.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Growth
Total Number of Employees
3

Valuation

Metric
GBLX
Price/Earnings (Normalized)
Price/Book Value
Price/Sales
Price/Cash Flow
Price/Earnings
GBLX

Financial Strength

Metric
GBLX
Quick Ratio
0.00
Current Ratio
0.03
Interest Coverage
−19.52
Quick Ratio
GBLX

Profitability

Metric
GBLX
Return on Assets (Normalized)
−149.71%
Return on Equity (Normalized)
Return on Invested Capital (Normalized)
Return on Assets
GBLX
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRQqp$550.2 Bil
VRTX
Vertex Pharmaceuticals IncDmpptff$111.1 Bil
REGN
Regeneron Pharmaceuticals IncZmqlgm$107.7 Bil
MRNA
Moderna IncQbhv$36.9 Bil
ARGX
argenx SE ADRWyjcw$24.2 Bil
BNTX
BioNTech SE ADRBnhw$22.3 Bil
ALNY
Alnylam Pharmaceuticals IncBsvvxz$19.9 Bil
BMRN
Biomarin Pharmaceutical IncDwqlrb$17.2 Bil
RPRX
Royalty Pharma PLC Class APwxdrh$13.9 Bil
INCY
Incyte CorpMjqgnrn$13.6 Bil

Sponsor Center